Creatine for Women Over 40: What the Trials Actually Show

The postmenopausal evidence is outcome-specific. Small pooled muscle signals do not establish a menopause treatment, a bone-density benefit or a universal personal dose.

Read the pooled result with its limits

A 2026 meta-analysis included seven randomized trials and 608 postmenopausal women, with a mean age around 62 years and interventions lasting 12–104 weeks.¹ It reported small pooled lean-mass and leg-press signals, while bone density was unchanged overall.

A long trial tests a different question

In a two-year trial, 237 postmenopausal women with a mean age of 59 received creatine 0.14 g/kg/day or placebo during resistance training and walking. Creatine did not improve the primary femoral-neck BMD outcome.²

Why the disclosure belongs beside the result

The 2026 review was not prospectively registered. Its disclosure states that one author chairs an Alzchem-supported creatine advisory board, that ISSN sometimes receives creatine-industry funding, and that Alzchem supported the remaining article-processing charge.¹ Disclosure does not invalidate a paper; it is context for independent review.

A bounded decision

Define whether the goal is strength, lean mass, function or bone health.
Do not transfer pooled findings into a guarantee for an individual.
Keep supplement identity, product quality and personal medical suitability as separate questions.
This article does not prescribe a dose or loading protocol.

Claim-level evidence

Sources and exact limits

Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: a systematic review and meta-analysis. Systematic review and meta-analysis. PMID 42141930. DOI 10.1080/15502783.2026.2668435. Design/population: Seven randomized placebo-controlled trials; 12–104 weeks; 608 postmenopausal women; mean age about 62 years. Limit: Small pooled lean-mass and strength signals; bone density unchanged overall; review was not prospectively registered and several trials had risk-of-bias concerns. Disclosure: RBK chairs an Alzchem-supported advisory board; ISSN sometimes receives industry funding; Alzchem supported the remaining article-processing charge. Checked 2026-09-02.
A 2-Year Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health. Randomized placebo-controlled trial. PMID 37144634. DOI 10.1249/MSS.0000000000003202. Design/population: Creatine 0.14 g/kg/day or placebo with resistance training and walking for two years; 237 postmenopausal women; mean age 59 years. Limit: Creatine did not improve the primary femoral-neck BMD outcome; secondary geometry findings require cautious interpretation. Disclosure: Funding: Canadian Institutes of Health Research (reference 130235) and Canada Foundation for Innovation. Author disclosures: Darren G. Candow disclosed industry-sponsored creatine research, donated creatine for studies, travel support for creatine-related scientific presentations, service on Alzchem’s Scientific Advisory Board, and expert-witness/consulting work in legal cases involving creatine. The paper does not give separate author-specific disclosure statements for the other authors; this is not confirmation that they had no conflicts. Original paper: Acknowledgments. Disclosure checked 2026-09-08.